Our Pipeline

Pioneering the development of therapeutics to modulate DNA Damage Response

DNA Damage Response Modulators

Our pipeline of DNA Damage Response modulators includes novel inhibitors of ATR and WEE1.

 

ATRN-119: Novel macrocyclic ATR inhibitor

  • Phase 1 clinical trial expected to commence 3Q, 2022

  • Unique biomarkers identified for optimized patient selection

  • Differentiated, macrocyclic molecular structure

  • Potential for lower hematological toxicity versus other ATR inhibitors

 

ATRN-W1051: Novel WEE1 inhibitor

  • Structurally differentiated from other WEE1 inhibitors

  • Excellent selectivity for WEE1 versus PLK1/2/3, potentially limiting off-target toxicity

  • Nanomolar anti-proliferative activity against multiple cancer cell lines

  • Promising anti-tumor activity in tumor model

  • Potential for improved PK properties versus other WEE1 inhibitors

  • IND-enabling studies expected to commence in 2H, 2022

DDR PIPELINE

 
program / target
molecule
discovery
optimization
IND-enabling
phase one
ATR
ATR
WEE1
Novel DDR Target
ATRN-119
Undisclosed
ATRN-W1051
Undisclosed